The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
Authors
Keywords
-
Journal
CLINICAL SCIENCE
Volume 132, Issue 4, Pages 489-507
Publisher
Portland Press Ltd.
Online
2018-03-01
DOI
10.1042/cs20180031
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Oral Dipeptidyl-Peptidase-4 Inhibitor Sitagliptin Increases Circulating Levels Of Stromal-Derived Factor-1 Alpha
- (2017) Athanasia Papazafiropoulou et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes
- (2017) Lea Duvnjak et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy
- (2017) Ahmed A Hasan et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Metabolomics for clinical use and research in chronic kidney disease
- (2017) Berthold Hocher et al. Nature Reviews Nephrology
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes
- (2017) Chia-Ter Chao et al. Oncotarget
- Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
- (2017) Sophia Zoungas et al. Lancet Diabetes & Endocrinology
- KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes
- (2017) Titli Nargis et al. Molecular Metabolism
- Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition
- (2016) Sen Shi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury
- (2016) Yuki Tanaka et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice
- (2016) Camila Manrique et al. Cardiovascular Diabetology
- Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
- (2016) C. Klemann et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of diabetic nephropathy in Chinese patients with newly diagnosed type 2 diabetes: A cross-sectional study
- (2016) Tianpeng Zheng et al. Diabetes & Vascular Disease Research
- Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
- (2016) Jan H. Cornel et al. DIABETES CARE
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- (2016) Ofri Mosenzon et al. DIABETES CARE
- Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON
- (2016) Muh Geot Wong et al. DIABETES CARE
- Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2016) Lennart Tonneijck et al. DIABETES CARE
- Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin-1 (CAV-1) pathway
- (2016) Valentina Vellecco et al. DIABETES OBESITY & METABOLISM
- Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial
- (2016) Christian Ott et al. DIABETOLOGIA
- Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort
- (2016) Carmen Wolke et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes
- (2016) Gian Paolo Fadini et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients
- (2016) Thomas Forst et al. JOURNAL OF HYPERTENSION
- Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure
- (2016) Gisela Schnapp et al. JOURNAL OF MEDICINAL CHEMISTRY
- The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy
- (2016) Oleg Tsuprykov et al. KIDNEY INTERNATIONAL
- Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
- (2016) Satoru Takashima et al. KIDNEY INTERNATIONAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unmet need in diabetic nephropathy: failed drugs or trials?
- (2016) Dick de Zeeuw et al. Lancet Diabetes & Endocrinology
- Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases
- (2016) Sonsoles Piera-Velazquez et al. Journal of Clinical Medicine
- Linagliptin Ameliorates Methylglyoxal-Induced Peritoneal Fibrosis in Mice
- (2016) Takuo Nagai et al. PLoS One
- Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis
- (2016) Swayam Prakash Srivastava et al. Scientific Reports
- Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes
- (2015) Mark E. Cooper et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications
- (2015) Sho-ichi Yamagishi et al. Cardiovascular Diabetology
- Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart
- (2015) Li-Hui Zhang et al. CARDIOVASCULAR DRUGS AND THERAPY
- Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial: Figure 1
- (2015) Markku Laakso et al. DIABETES CARE
- Anisotropy and roughness of the solid-liquid interface of BCC Fe
- (2015) Yongli Sun et al. JOURNAL OF MOLECULAR MODELING
- Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition
- (2015) Sen Shi et al. KIDNEY INTERNATIONAL
- Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin
- (2015) Michael Zeisberg et al. KIDNEY INTERNATIONAL
- Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis
- (2015) Takanori Matsui et al. LABORATORY INVESTIGATION
- Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
- (2015) Merlin C. Thomas et al. Nature Reviews Nephrology
- The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose
- (2015) S.M. Salheen et al. PHARMACOLOGICAL RESEARCH
- MicroRNAs in renal fibrosis
- (2015) Arthur C.-K. Chung et al. Frontiers in Physiology
- The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis
- (2015) Yannick Waumans et al. Frontiers in Immunology
- A DPP-4 Inhibitor Suppresses Fibrosis and Inflammation on Experimental Autoimmune Myocarditis in Mice
- (2015) Hiroyuki Hirakawa et al. PLoS One
- Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin
- (2015) Muralikrishna Gangadharan Komala et al. PLoS One
- DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure
- (2014) Nobutaka Koibuchi et al. Cardiovascular Diabetology
- DPP-4 Inhibitors—Renoprotection in Diabetic Nephropathy?
- (2014) Usha Panchapakesan et al. DIABETES
- Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
- (2014) Keizo Kanasaki et al. DIABETES
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
- (2014) Erin E. Mulvihill et al. ENDOCRINE REVIEWS
- Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4
- (2014) Volker Vallon et al. EXPERIMENTAL PHYSIOLOGY
- Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis
- (2014) S. Nakashima et al. HORMONE AND METABOLIC RESEARCH
- Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity
- (2014) Sho-ichi Yamagishi et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy
- (2014) Yuliya Sharkovska et al. JOURNAL OF HYPERTENSION
- Significance of Vascular Dipeptidyl Peptidase-4 Inhibition on Vascular Protection in Zucker Diabetic Fatty Rats
- (2014) Shinji Takai et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in Chinese without diabetes: a four-year prospective study
- (2014) T. Zheng et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat
- (2014) Ravi Nistala et al. Obesity
- Soluble DPP4 originates in part from bone marrow cells and not from the kidney
- (2014) Zhendi Wang et al. PEPTIDES
- N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition
- (2014) Takako Nagai et al. Biomed Research International
- Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
- (2013) Yuji Ishibashi et al. Cardiovascular Diabetology
- Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials
- (2013) Maximilian von Eynatten et al. Cardiovascular Diabetology
- Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease
- (2013) Jianhua He et al. Clinical and Experimental Nephrology
- Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
- (2013) P.-H. Groop et al. DIABETES CARE
- Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension
- (2013) Lyubov Chaykovska et al. JOURNAL OF HYPERTENSION
- Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
- (2013) Vlado Perkovic et al. KIDNEY INTERNATIONAL
- MicroRNAs in Kidney Fibrosis and Diabetic Nephropathy: Roles on EMT and EndMT
- (2013) Swayam Prakash Srivastava et al. Biomed Research International
- KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
- (2012) AMERICAN JOURNAL OF KIDNEY DISEASES
- Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition
- (2012) Swenja Kröller-Schön et al. CARDIOVASCULAR RESEARCH
- Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
- (2012) Larry K. Golightly et al. CLINICAL PHARMACOKINETICS
- Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease
- (2012) Ai-li Sun et al. Diabetes & Vascular Disease Research
- Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study
- (2012) J. B. McGill et al. DIABETES CARE
- Dipeptidyl Peptidase IV Regulates Proliferation of Preglomerular Vascular Smooth Muscle and Mesangial Cells
- (2012) Edwin K. Jackson et al. HYPERTENSION
- Pathophysiology of the aging kidney and therapeutic interventions
- (2012) Keizo Kanasaki et al. HYPERTENSION RESEARCH
- The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats
- (2012) Berthold Hocher et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy
- (2012) Markus L. Alter et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Renal and Cardiac Effects of DPP-4 Inhibitors from Preclinical Development to Clinical Research
- (2012) Berthold Hocher et al. KIDNEY & BLOOD PRESSURE RESEARCH
- FGF Regulates TGF-β Signaling and Endothelial-to-Mesenchymal Transition via Control of let-7 miRNA Expression
- (2012) Pei-Yu Chen et al. Cell Reports
- Role of Endothelial-Mesenchymal Transition (EndoMT) in the Pathogenesis of Fibrotic Disorders
- (2011) Sonsoles Piera-Velazquez et al. AMERICAN JOURNAL OF PATHOLOGY
- Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*
- (2011) U. Graefe-Mody et al. DIABETES OBESITY & METABOLISM
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
- (2011) Lyubov Chaykovska et al. PLoS One
- Transforming Growth Factor-β1 Induces Smad3-Dependent β1 Integrin Gene Expression in Epithelial-to-Mesenchymal Transition during Chronic Tubulointerstitial Fibrosis
- (2010) Yi-Chun Yeh et al. AMERICAN JOURNAL OF PATHOLOGY
- The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Exhibits Time- and Dose-Dependent Localization in Kidney, Liver, and Intestine after Intravenous Dosing: Results from High Resolution Autoradiography in Rats
- (2010) A. Greischel et al. DRUG METABOLISM AND DISPOSITION
- The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
- (2010) S. Blech et al. DRUG METABOLISM AND DISPOSITION
- Renal Medullary MicroRNAs in Dahl Salt-Sensitive Rats
- (2010) Yong Liu et al. HYPERTENSION
- Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
- (2010) Faramarz Ismail-Beigi et al. LANCET
- Conversion of vascular endothelial cells into multipotent stem-like cells
- (2010) Damian Medici et al. NATURE MEDICINE
- SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury
- (2010) G. Stokman et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Endothelial–Mesenchymal Transition as a Novel Mechanism for Generating Myofibroblasts during Diabetic Nephropathy
- (2009) Akane Kizu et al. AMERICAN JOURNAL OF PATHOLOGY
- Endothelial-Myofibroblast Transition Contributes to the Early Development of Diabetic Renal Interstitial Fibrosis in Streptozotocin-Induced Diabetic Mice
- (2009) Jinhua Li et al. AMERICAN JOURNAL OF PATHOLOGY
- Loss of β1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model
- (2009) Shangxi Liu et al. ARTHRITIS AND RHEUMATISM
- Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats
- (2009) Holger Fuchs et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside
- (2009) Marc Vanderheyden et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans
- (2009) Markus P Schlaich et al. JOURNAL OF HYPERTENSION
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors
- (2008) L. Thomas et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Fibroblasts in Kidney Fibrosis Emerge via Endothelial-to-Mesenchymal Transition
- (2008) E. M. Zeisberg et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started